Cargando…

Activation of the AMPK-SIRT1 pathway contributes to protective effects of Salvianolic acid A against lipotoxicity in hepatocytes and NAFLD in mice

Background: Salvianolic acid A (Sal A), a natural polyphenol compound extracted from Radix Salvia miltiorrhiza (known as Danshen in China), possesses a variety of potential pharmacological activities. The aim of this study is to determine mechanisms of hepatoprotective effects of Sal A against lipot...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Songtao, Qian, Qianyu, Ying, Na, Lai, Jianfei, Feng, Luyan, Zheng, Sitong, Jiang, Fusheng, Song, Qing, Chai, Hui, Dou, Xiaobing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7734334/
https://www.ncbi.nlm.nih.gov/pubmed/33328983
http://dx.doi.org/10.3389/fphar.2020.560905
_version_ 1783622454580609024
author Li, Songtao
Qian, Qianyu
Ying, Na
Lai, Jianfei
Feng, Luyan
Zheng, Sitong
Jiang, Fusheng
Song, Qing
Chai, Hui
Dou, Xiaobing
author_facet Li, Songtao
Qian, Qianyu
Ying, Na
Lai, Jianfei
Feng, Luyan
Zheng, Sitong
Jiang, Fusheng
Song, Qing
Chai, Hui
Dou, Xiaobing
author_sort Li, Songtao
collection PubMed
description Background: Salvianolic acid A (Sal A), a natural polyphenol compound extracted from Radix Salvia miltiorrhiza (known as Danshen in China), possesses a variety of potential pharmacological activities. The aim of this study is to determine mechanisms of hepatoprotective effects of Sal A against lipotoxicity both in cultured hepatocytes and in a mouse model of fatty liver disease. Methods: High-fat and high-carbohydrate diet (HFCD)-fed C57BL/6J mice were employed to establish hepatic lipotoxicity in a mouse model. Two doses of Sal A were administered every other day via intraperitoneal injection (20 and 40 mg/kg BW, respectively). After a 10-week intervention, liver injury was detected by immunohistochemical and biochemical analyses. For in vitro studies, we used HepG2, a human hepatoma cell line, and exposed them to palmitic acid to induce lipotoxicity. The protective effects of Sal A on palmitic acid-induced lipotoxicity were examined in Sal A-pretreated HepG2 cells. Results: Sal A treatments attenuated body weight gain, liver injury, and hepatic steatosis in mice exposed to HFCD. Sal A pretreatments ameliorated palmitic acid-induced cell death but did not reverse effects of HFCD- or palmitate-induced activations of JNK, ERK1/2, and PKA. Induction of p38 phosphorylation was significantly reversed by Sal A in HFCD-fed mice but not in palmitate-treated HepG2 cells. However, Sal A rescued hepatic AMP-activated protein kinase (AMPK) suppression and sirtuin 1 (SIRT1) downregulation by both HFCD feeding in mice and exposure to palmitate in HepG2 cells. Sal A dose-dependently up-regulated p-AMPK and SIRT1 protein levels. Importantly, siRNA silencing of either AMPK or SIRT1 gene expression abolished the protective effects of Sal A on lipotoxicity. Moreover, while AMPK silencing blocked Sal A-induced SIRT1, silencing of SIRT1 had no effect on Sal A-triggered AMPK activation, suggesting SIRT1 upregulation by Sal A is mediated by AMPK activation. Conclusion: Our data uncover a novel mechanism for hepatoprotective effects of Sal A against lipotoxicity both in livers from HFCD-fed mice and palmitic acid-treated hepatocytes.
format Online
Article
Text
id pubmed-7734334
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-77343342020-12-15 Activation of the AMPK-SIRT1 pathway contributes to protective effects of Salvianolic acid A against lipotoxicity in hepatocytes and NAFLD in mice Li, Songtao Qian, Qianyu Ying, Na Lai, Jianfei Feng, Luyan Zheng, Sitong Jiang, Fusheng Song, Qing Chai, Hui Dou, Xiaobing Front Pharmacol Pharmacology Background: Salvianolic acid A (Sal A), a natural polyphenol compound extracted from Radix Salvia miltiorrhiza (known as Danshen in China), possesses a variety of potential pharmacological activities. The aim of this study is to determine mechanisms of hepatoprotective effects of Sal A against lipotoxicity both in cultured hepatocytes and in a mouse model of fatty liver disease. Methods: High-fat and high-carbohydrate diet (HFCD)-fed C57BL/6J mice were employed to establish hepatic lipotoxicity in a mouse model. Two doses of Sal A were administered every other day via intraperitoneal injection (20 and 40 mg/kg BW, respectively). After a 10-week intervention, liver injury was detected by immunohistochemical and biochemical analyses. For in vitro studies, we used HepG2, a human hepatoma cell line, and exposed them to palmitic acid to induce lipotoxicity. The protective effects of Sal A on palmitic acid-induced lipotoxicity were examined in Sal A-pretreated HepG2 cells. Results: Sal A treatments attenuated body weight gain, liver injury, and hepatic steatosis in mice exposed to HFCD. Sal A pretreatments ameliorated palmitic acid-induced cell death but did not reverse effects of HFCD- or palmitate-induced activations of JNK, ERK1/2, and PKA. Induction of p38 phosphorylation was significantly reversed by Sal A in HFCD-fed mice but not in palmitate-treated HepG2 cells. However, Sal A rescued hepatic AMP-activated protein kinase (AMPK) suppression and sirtuin 1 (SIRT1) downregulation by both HFCD feeding in mice and exposure to palmitate in HepG2 cells. Sal A dose-dependently up-regulated p-AMPK and SIRT1 protein levels. Importantly, siRNA silencing of either AMPK or SIRT1 gene expression abolished the protective effects of Sal A on lipotoxicity. Moreover, while AMPK silencing blocked Sal A-induced SIRT1, silencing of SIRT1 had no effect on Sal A-triggered AMPK activation, suggesting SIRT1 upregulation by Sal A is mediated by AMPK activation. Conclusion: Our data uncover a novel mechanism for hepatoprotective effects of Sal A against lipotoxicity both in livers from HFCD-fed mice and palmitic acid-treated hepatocytes. Frontiers Media S.A. 2020-11-30 /pmc/articles/PMC7734334/ /pubmed/33328983 http://dx.doi.org/10.3389/fphar.2020.560905 Text en Copyright © 2020 Li, Qian, Ying, Lai, Feng, Zheng, Jiang, Song, Chai and Dou http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Pharmacology
Li, Songtao
Qian, Qianyu
Ying, Na
Lai, Jianfei
Feng, Luyan
Zheng, Sitong
Jiang, Fusheng
Song, Qing
Chai, Hui
Dou, Xiaobing
Activation of the AMPK-SIRT1 pathway contributes to protective effects of Salvianolic acid A against lipotoxicity in hepatocytes and NAFLD in mice
title Activation of the AMPK-SIRT1 pathway contributes to protective effects of Salvianolic acid A against lipotoxicity in hepatocytes and NAFLD in mice
title_full Activation of the AMPK-SIRT1 pathway contributes to protective effects of Salvianolic acid A against lipotoxicity in hepatocytes and NAFLD in mice
title_fullStr Activation of the AMPK-SIRT1 pathway contributes to protective effects of Salvianolic acid A against lipotoxicity in hepatocytes and NAFLD in mice
title_full_unstemmed Activation of the AMPK-SIRT1 pathway contributes to protective effects of Salvianolic acid A against lipotoxicity in hepatocytes and NAFLD in mice
title_short Activation of the AMPK-SIRT1 pathway contributes to protective effects of Salvianolic acid A against lipotoxicity in hepatocytes and NAFLD in mice
title_sort activation of the ampk-sirt1 pathway contributes to protective effects of salvianolic acid a against lipotoxicity in hepatocytes and nafld in mice
topic Pharmacology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7734334/
https://www.ncbi.nlm.nih.gov/pubmed/33328983
http://dx.doi.org/10.3389/fphar.2020.560905
work_keys_str_mv AT lisongtao activationoftheampksirt1pathwaycontributestoprotectiveeffectsofsalvianolicacidaagainstlipotoxicityinhepatocytesandnafldinmice
AT qianqianyu activationoftheampksirt1pathwaycontributestoprotectiveeffectsofsalvianolicacidaagainstlipotoxicityinhepatocytesandnafldinmice
AT yingna activationoftheampksirt1pathwaycontributestoprotectiveeffectsofsalvianolicacidaagainstlipotoxicityinhepatocytesandnafldinmice
AT laijianfei activationoftheampksirt1pathwaycontributestoprotectiveeffectsofsalvianolicacidaagainstlipotoxicityinhepatocytesandnafldinmice
AT fengluyan activationoftheampksirt1pathwaycontributestoprotectiveeffectsofsalvianolicacidaagainstlipotoxicityinhepatocytesandnafldinmice
AT zhengsitong activationoftheampksirt1pathwaycontributestoprotectiveeffectsofsalvianolicacidaagainstlipotoxicityinhepatocytesandnafldinmice
AT jiangfusheng activationoftheampksirt1pathwaycontributestoprotectiveeffectsofsalvianolicacidaagainstlipotoxicityinhepatocytesandnafldinmice
AT songqing activationoftheampksirt1pathwaycontributestoprotectiveeffectsofsalvianolicacidaagainstlipotoxicityinhepatocytesandnafldinmice
AT chaihui activationoftheampksirt1pathwaycontributestoprotectiveeffectsofsalvianolicacidaagainstlipotoxicityinhepatocytesandnafldinmice
AT douxiaobing activationoftheampksirt1pathwaycontributestoprotectiveeffectsofsalvianolicacidaagainstlipotoxicityinhepatocytesandnafldinmice